2015 News Releases

Webcast ImageWebcast - Live
AtriCure, Inc. at JMP Securities Life Sciences Conference
06/24/15 at 9:00 a.m. ET
AtriCure, Inc. at JMP Securities Life Sciences Conference
Wednesday, June 24, 2015 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2015 | 2014 | 2013 | 2012 | 2011
DateTitle 
06/02/15AtriCure to Present at the JMP Securities Life Sciences Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jun. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the JMP Securities Life Sciences Conference at the St. Regis in New York on Wednesday, June 24, 2015. Management is scheduled to present at 9:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiti... 
Printer Friendly Version
04/29/15AtriCure Reports First Quarter 2015 Financial Results and Updates 2015 Outlook
Revenue of $29.9 million – up 20.3% as reported, 24% constant currency U.S. sales of $22.9 million – up 26.3% International sales of $7.0 million – up 3.9% as reported, 17.6% constant currency WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 29, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, ... 
Printer Friendly Version
04/21/15AtriClip System Surpasses 50,000 Units Sold Worldwide
AtriClip is the most widely used device globally for left atrial appendage management WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 21, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced it has sold more than 50,000 AtriClip® Left Atrial Appendage Exclusion System devices worldwide, making it not only the preferred surgi... 
Printer Friendly Version
04/08/15AtriCure to Announce First Quarter 2015 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 8, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, will release its financial results for the first quarter of 2015 on Wednesday, April 29, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, April 29, 2015 to discuss its first quarter 2015 financial resul... 
Printer Friendly Version
04/07/15AATS Graham Foundation and AtriCure Announce James L. Cox Fellowship in Atrial Fibrillation Surgery
Fellowship provides newly graduated cardiothoracic surgeons with a unique opportunity to be trained by nationally recognized experts in atrial fibrillation surgery WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 7, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, together with the American Association for Thoracic Surgery ... 
Printer Friendly Version
03/25/15AtriCure to Present at the Needham Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 25, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Needham Healthcare Conference at the Westin Grand Central Hotel in New York on Tuesday, April 14, 2015. Management is scheduled to present at 8:00 a.m. Eastern Time. A live audio webcast of the presentation may be accessed by... 
Printer Friendly Version
03/18/15AtriCure Launches Solution for Treatment of Post-Thoracotomy Pain
The CryoICE® cryo ablation probe is now available for cryoanalgesia therapy WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 18, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced that it has launched the availability of its cryoICE cryo ablation probe (CRYO2) to provide cryoanalgesia for temporary pain m... 
Printer Friendly Version
03/05/15AtriCure Announces 2015 Analyst & Investor Meeting
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 5, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will host an analyst and institutional investor meeting on Tuesday, March 24, 2015, in New York City from 8:00 a.m. to approximately 10:00 a.m. Eastern Time. The meeting will include remarks from the AtriCure management team highlighting the company’s strategy for execu... 
Printer Friendly Version
03/03/15AtriCure to Present at the Barclays Capital Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Mar. 3, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Barclays Capital Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, Florida on Tuesday, March 10, 2015. Management is scheduled to present at 8:30 a.m. Eastern Time. A live audio webcast of the present... 
Printer Friendly Version
02/24/15First Two Patients Enrolled and Treated in AtriCure’s Landmark Afib Study
The collaborative study between cardiac surgeons and electrophysiologists to deliver innovative solutions and new treatment options for Atrial Fibrillation WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 24, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation (Afib) and left atrial appendage management, today announced the first two patients have been enrolled and ... 
Printer Friendly Version
02/23/15AtriCure Reports Fourth Quarter and Full Year 2014 Financial Results
2014 revenue of $107.5 million – up 31.2% 2014 U.S. sales of $80.2 million – up 28.7% 2014 International sales of $27.3 million – up 39.2%; 39.8% constant currency Fourth quarter 2014 revenue of $29.4 million – up 34.4% WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 23, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and l... 
Printer Friendly Version
02/02/15AtriCure to Announce Fourth Quarter and Full Year 2014 Financial Results
WEST CHESTER, Ohio--(BUSINESS WIRE)--Feb. 2, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, will release its financial results for the fourth quarter and full year 2014 on Monday, February 23, 2015. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Monday, February 23, 2015 to discuss its fourth quarter and full year 2014 financi... 
Printer Friendly Version
01/19/15AtriCure to Present at the Leerink Global Healthcare Conference
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 19, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Leerink Global Healthcare Conference at the Waldorf Astoria Hotel in New York on Thursday, February 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast and replay of the presentation w... 
Printer Friendly Version
01/14/15Douglas Seith Assumes the Role of AtriCure Chief Operating Officer; Andy Wade Promoted to Senior Vice President
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 14, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that Douglas Seith will assume the role of Chief Operating Officer. Mr. Seith will now be responsible for all global commercial organizations as well as education and clinical science programs. The company also announced that Andy Wade has been promoted... 
Printer Friendly Version
01/12/15AtriCure Announces Preliminary Results for Fourth Quarter and Full Year 2014 Issues 2015 Guidance
WEST CHESTER, Ohio--(BUSINESS WIRE)--Jan. 12, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (“Afib”) and Left Atrial Appendage Management (“LAAM”), today announced preliminary financial results for fourth quarter and full year 2014 and issued 2015 financial guidance. Preliminary and unaudited revenue for fourth quarter 2014 is expected to be approximately $29.5 million, reflecting growth ... 
Printer Friendly Version